Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1936 to 1950 of 2187 results for guidelines

  1. Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.

  2. Prontosan for treating acute and chronic wounds (HTG616)

    Evidence-based recommendations on Prontosan for treating acute and chronic wounds.

  3. Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

    Discontinued Reference number: GID-TA10202

  4. AmnioSense for unexplained vaginal wetness in pregnancy (MIB198)

    NICE has developed a medtech innovation briefing (MIB) on AmnioSense for unexplained vaginal wetness in pregnancy .

  5. Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (TA1108)

    Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.

  6. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    studies available that compared the types of surgery when it published its guideline and found that: : It isn't possible to say for sure...

  7. KardiaMobile for detecting atrial fibrillation (HTG606)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

  8. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

  9. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.

  10. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

  11. Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.

  12. Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)

    Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.

  13. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.

  14. The Insides System for managing intestinal failure (MIB286)

    NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .

  15. Proov Confirm for ovulation confirmation (MIB322)

    NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .